CLSN - セルシオン (Celsion Corporation) セルシオン



symbol CLSN
会社名 Celsion Corp (セルシオン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 セルシオン(Celsion Corporation)は治療が難しい癌の患者向けの治療法の開発するを中心とする腫瘍薬品の開発企業。平成23年12月31日現在、同社の主力商品「ThermoDox」は、肝臓癌に対する「HEAT」研究と呼ばれる第3相臨床試験、大腸癌の肝臓転移に対する第2相臨床研究及び再発性胸壁乳癌に対する第2相臨床研究において評価されている。「ThermoDox」はリポソームカプセル化したドキソルビシンであり、各種癌の治療でよく使用される認可を受けた腫瘍薬品である。軽度の温熱療法でのローカライズされた熱はリポソームから封入ドキソルビシンを放出して、高濃度のドキソルビシンが対象となる腫瘍またはその周辺で優先的に堆積されることを可能にする。リポソームは、超顕微鏡で製造された小胞体であり、自然に発生する脂肪が含まれる膜二重層に囲まれた離散的な水系中心コンパートメントを含む。   セルシオンは、米国の医薬品開発会社。癌に苦しむ人々の治療法を開発する。独自の熱活性化リポソ―ム技術をベ―スにタ―ゲットを絞った化学療法腫瘍薬を開発し、商品化に取り組む。主要製品である癌治療薬「サ―モドックス」は、原発性肝癌を対象とした第3相臨床試験と、再発胸壁の乳癌治療を対象にした第2相臨床試験で評価されている。   Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
本社所在地 997 Lenox Drive Suite 100 Lawrenceville NJ 08648 USA
代表者氏名 Jeffrey Wayne Church ジェフリー・ウェイン教会
代表者役職名 Chief Financial Officer Senior Vice President Corporate Secretary IR Contact Officer
電話番号 +1 609-896-9100
設立年月日 30072
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 19人
EBITDA EBITDA(百万ドル) -20.93515
終値(lastsale) 2.65
時価総額(marketcap) 47027655.25
時価総額 時価総額(百万ドル) 44.59869
売上高 売上高(百万ドル) 0.50000
企業価値(EV) 企業価値(EV)(百万ドル) 27.62501
当期純利益 当期純利益(百万ドル) -23.05973
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Celsion Corporation revenues remained flat at $250K. Net loss applicable to common stockholders increased 22% to $12.7M. Revenues reflect market conditions. Higher net loss reflects Selling General_Administrative increase of 67% to $5.2M (expense) Research and development increase of 12% to $7.3M (expense) Other (expense) income decrease from $3K (income) to $0K.



   Celsion changes name to Imunon (IMNN)  2022/09/19 20:36:45 Seeking Alpha
Celsion (CLSN) announced Monday its decision to change company''s name to Imunon. The new name of clinical-stage drug development company is claimed to outline the "evolution of its…
   Celsion Earnings Perspective: Return On Capital Employed  2022/09/09 14:17:30 Benzinga
According to Benzinga Pro data, during Q2, Celsion (NASDAQ: CLSN ) posted sales of $125 thousand. Earnings were up 42.31%, but Celsion still reported an overall loss of $6.04 million. Celsion collected $125 thousand in revenue during Q1, but reported earnings showed a $10.47 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on
   Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference  2022/09/07 13:15:00 GlobeNewswire
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference. The hybrid conference will be held from September 12-14 with in-person participation held at the Lotte New York Palace Hotel.
   Celsion says additional data shows placcine vaccine works against COVID-19 in animal model  2022/09/01 13:27:29 Seeking Alpha
Celsion (CLSN) said on Thursday that additional data from its completed proof-of-concept mouse challenge study confirmed that its DNA-based placcine vaccine can produce robust levels…
   Celsion Corporation''s (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript  2022/08/15 19:31:11 Seeking Alpha
Celsion Corporation (NASDAQ:NASDAQ:CLSN) Q2 2022 Earnings Conference Call August 15, 2022, 11:00 am ET Company Participants Monique Kosse - IR, LifeSci Advisors Michael Tardugno - Executive…
   Celsion adds Moderna chief commercial officer as CEO  2022/07/19 12:53:18 Seeking Alpha
Clinical-stage biotech Celsion Corporation (CLSN) announced on Tuesday that the company appointed Corinne Le Goff as its President and Chief Executive Officer effective July 18, 2022
   Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2022 Results - Earnings Call Transcript  2022/05/16 19:26:06 Seeking Alpha
Celsion Corporation (NASDAQ:NASDAQ:CLSN) Q1 2022 Earnings Conference Call May 16, 2022 11:00 ET Company Participants Monique Kosse - Investor Relations Michael Tardugno - Chairman, Chief…
   Celsion: Q1 Earnings Insights  2022/05/16 12:16:12 Benzinga
Celsion (NASDAQ: CLSN ) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Celsion missed estimated earnings by 83.84%, reporting an EPS … Full story available on
   Celsion GAAP EPS of -$1.82 misses by $0.82, revenue of $0.13M beats by $0.02M  2022/05/16 12:04:01 Seeking Alpha
Celsion press release (CLSN): Q1 GAAP EPS of -$1.82 misses by $0.82.Revenue of $0.13M (flat Y/Y) beats by $0.02M.The Company had $47.3 million in cash, investments and restricted…
   Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update  2022/05/16 12:00:00 GlobeNewswire
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT
   Celsion Corp Shares Fall 1.4% Below Previous 52-Week Low - Market Mover  2021/12/28 05:50:11 Kwhen Finance
Celsion Corp (CLSN) shares closed 1.4% lower than its previous 52 week low, giving the company a market cap of $54M. The stock is currently down 12.2% year-to-date, down 15.1% over the past 12 months, and down 87.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 28.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -47.4% The company's stock price performance over the past 12 months beats the peer average by -47.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at Write to © 2020 Kwhen Inc.
   Investors Alert (ATR Analysis): AT&T Inc. (NYSE:T), Celsion Corporation (NASDAQ:CLSN)  2021/12/23 23:09:23 Stock Equity
AT&T Inc. (NYSE:T) with the stream of 0.36% also noticed, India Celsion Corporation (NASDAQ:CLSN) encountered a rapid change of -2.62% in the last hour of Thursdays trading session. AT&T Inc. The post Investors Alert (ATR Analysis): AT&T Inc. (NYSE:T), Celsion Corporation (NASDAQ:CLSN) appeared first on Stocks Equity .
   Hair-raising Facts to Know: Sundial Growers Inc. (NASDAQ:SNDL), Celsion Corporation (NASDAQ:CLSN)  2021/12/15 23:22:41 Stock Equity
Sundial Growers Inc. (NASDAQ:SNDL) with the stream of -0.37% also noticed, India Celsion Corporation (NASDAQ:CLSN) encountered a rapid change of 2.87% in the last hour of Wednesdays trading session. Sundial The post Hair-raising Facts to Know: Sundial Growers Inc. (NASDAQ:SNDL), Celsion Corporation (NASDAQ:CLSN) appeared first on Stocks Equity .
   State Street Corp Makes New Investment in Celsion Co. (NASDAQ:CLSN)  2021/12/09 09:20:42 Transcript Daily
State Street Corp bought a new position in shares of Celsion Co. (NASDAQ:CLSN) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 214,568 shares of the biotechnology companys stock, valued at approximately $273,000. A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セルシオン CLSN Celsion Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)